Skip to main content

Advertisement

Table 1 Baseline study characteristics, overall and stratified by hepatitis C virus co-infection

From: Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy

  Overall (n = 2595) HCV positive (n = 484) HCV negative (n = 1978) Unknown (n = 133)
Median age (IQR), years 40 (33, 46) 41 (35, 47) 39 (33, 46) 41 (36, 49)
Male sex 2195 (85%) 394 (81%) 1690 (85%) 111 (83%)
African/Caribbean ethnicity a 368 (24%) 17 (5%) 344 (29%) 17 (27%)
Median eGFR (IQR), mL/min/1.73 m2 105 (92, 116) 103 (91, 114) 105 (92, 117) 106 (96, 115)
Injection drug use as HIV risk factor b 389 (18%) 302 (69%) 83 (5%) 4 (4%)
Median CD4+ cell count (IQR), cells/μL 210 (102, 318) 190 (80, 290) 220 (110, 323) 200 (100, 319)
Median HIV viral load (IQR), log10 copies/mL 4.9 (4.4, 5.2) 4.9 (4.4, 5.1) 4.9 (4.4, 5.2) 4.9 (4.4, 5.2)
Previous AIDS-defining event c 450 (19%) 99 (22%) 331 (19%) 20 (18%)
Tenofovir use 1410 (54%) 227 (47%) 1111 (56%) 72 (54%)
Atazanavir use 666 (26%) 144 (30%) 494 (25%) 28 (21%)
Lopinavir use 471 (18%) 99 (20%) 347 (18%) 25 (19%)
Median year of cART initiation (IQR) 2007 (2004, 2009) 2006 (2003, 2009) 2008 (2004, 2009) 2008 (2004, 2010)
Liver fibrosis (APRI ≥1.5) d 145 (7%) 69 (17%) 71 (5%) 5 (6%)
Diabetes e 119 (5%) 26 (6%) 89 (5%) 4 (3%)
Hypertension f 74 (12%) 13 (15%) 59 (12%) 2 (8%)
Cohort province
 British Columbia 1103 (43%) 307 (63%) 738 (37%) 58 (44%)
 Ontario 838 (32%) 110 (23%) 694 (35%) 34 (26%)
 Québec 654 (25%) 67 (14%) 546 (28%) 41 (31%)
  1. APRI aspartate aminotransferase to platelet ratio index, cART combination antiretroviral therapy, IQR interquartile range, eGFR estimated glomerular filtration rate, HCV hepatitis C virus
  2. a 1045 participants (40%) are missing data on African/Caribbean ethnicity; 138 among HCV Positive, 838 among HCV Negative, and 69 among the Unknown
  3. b 431 participants (17%) are missing data on injection drug use risk factor; 44 among HCV Positive, 344 among HCV Negative, and 43 among the Unknown
  4. c 246 participants (9%) are missing previous AIDS event histories; 31 among HCV Positive, 197 among HCV Negative, and 18 among the Unknown
  5. d 603 participants (23%) are missing data on liver fibrosis; 73 among HCV Positive, 484 among HCV Negative, and 46 among the Unknown
  6. e 142 participants (5%) are missing data on diabetes; 13 among HCV Positive, 111 among HCV Negative, and 18 among the Unknown
  7. f 1973 participants (76%) are missing data on hypertension; 395 among HCV Positive, 1470 among HCV Negative, and 108 among the Unknown